Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$14.28 USD
+0.06 (0.42%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $14.27 -0.01 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
A Value D Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3,263 | 4,097 | 7,788 | 9,427 | 6,012 |
Receivables | 4,814 | 5,045 | 6,447 | 7,640 | 7,221 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8,348 | 7,300 | 7,593 | 7,086 | 6,988 |
Other Current Assets | 1,230 | 1,303 | 1,256 | 1,349 | 2,498 |
Total Current Assets | 17,654 | 17,745 | 23,083 | 25,501 | 22,719 |
Net Property & Equipment | 13,729 | 12,515 | 14,087 | 13,667 | 12,755 |
Investments & Advances | 2,971 | 2,804 | 2,938 | 3,274 | 3,399 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2,718 | 2,708 | 3,227 | 3,325 | 2,835 |
Intangibles | 66,825 | 67,047 | 73,214 | 74,664 | 75,292 |
Deposits & Other Assets | 353 | 469 | 735 | 943 | 955 |
Total Assets | 104,251 | 103,287 | 117,284 | 121,376 | 117,954 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3,778 | 4,804 | 4,595 | 3,232 | 2,933 |
Current Portion Long-Term Debt | 2,534 | 2,513 | 1,816 | 208 | 5,399 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 758 | 1,720 | 1,788 | 1,365 | 1,681 |
Other Current Liabilities | 8,890 | 9,329 | 10,898 | 11,863 | 10,005 |
Total Current Liabilities | 15,960 | 18,366 | 19,097 | 16,668 | 20,018 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 785 | 2,003 | 4,018 | 5,103 | 6,533 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30,888 | 29,916 | 36,859 | 43,364 | 41,460 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6,427 | 5,978 | 6,727 | 7,575 | 6,450 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 54,060 | 56,263 | 66,701 | 72,710 | 74,461 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 11,569 | 12,405 | 14,919 | 15,681 | 15,347 |
Capital Surplus | 12,057 | 12,793 | 15,209 | 15,871 | 15,459 |
Retained Earnings | 9,599 | 11,404 | 13,169 | 14,193 | 12,604 |
Other Equity | 17,319 | 11,164 | 8,319 | 3,480 | 888 |
Treasury Stock | 354 | 742 | 1,032 | 560 | 805 |
Total Shareholder's Equity | 50,191 | 47,025 | 50,583 | 48,665 | 43,493 |
Total Liabilities & Shareholder's Equity | 104,251 | 103,287 | 117,284 | 121,376 | 117,954 |
Total Common Equity | 50,191 | 47,025 | 50,583 | 48,665 | 43,493 |
Shares Outstanding | 3,164.80 | 3,164.50 | 3,100.70 | 3,155.70 | 3,152.70 |
Book Value Per Share | 15.86 | 14.86 | 16.31 | 15.42 | 13.80 |
Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5,489 | 3,263 | 2,158 | 2,303 | 2,691 |
Receivables | 4,943 | 4,814 | 5,053 | 5,438 | 6,026 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 8,171 | 8,348 | 7,954 | 7,975 | 7,909 |
Other Current Assets | 1,285 | 1,230 | 1,351 | 1,272 | 1,420 |
Total Current Assets | 19,888 | 17,654 | 16,516 | 16,988 | 18,046 |
Net Property & Equipment | 13,346 | 13,729 | 12,522 | 13,070 | 13,106 |
Investments & Advances | 2,862 | 2,971 | 2,536 | 2,873 | 2,873 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2,442 | 2,718 | 2,153 | 2,320 | 2,741 |
Intangibles | 64,639 | 66,825 | 62,617 | 66,954 | 70,782 |
Deposits & Other Assets | 679 | 353 | 372 | 412 | 439 |
Total Assets | 103,857 | 104,251 | 96,716 | 102,616 | 107,987 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3,001 | 3,778 | 3,289 | 2,905 | 3,219 |
Current Portion Long-Term Debt | 2,808 | 2,534 | 2,518 | 1,896 | 3,043 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1,038 | 758 | 765 | 899 | 1,772 |
Other Current Liabilities | 8,930 | 8,890 | 8,947 | 10,636 | 10,229 |
Total Current Liabilities | 15,777 | 15,960 | 15,519 | 16,337 | 18,263 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 355 | 785 | 905 | 1,578 | 1,968 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 32,270 | 30,888 | 29,198 | 30,390 | 31,611 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5,539 | 5,245 | 5,521 | 5,618 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 53,942 | 54,060 | 50,866 | 53,826 | 57,459 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 10,730 | 11,569 | 11,400 | 11,568 | 12,238 |
Capital Surplus | 11,263 | 12,057 | 11,765 | 11,807 | 12,716 |
Retained Earnings | 8,564 | 9,599 | 9,499 | 9,978 | 10,878 |
Other Equity | 19,683 | 17,319 | 13,534 | 15,792 | 15,428 |
Treasury Stock | 326 | 354 | 349 | 354 | 732 |
Total Shareholder's Equity | 49,915 | 50,191 | 45,850 | 48,790 | 50,528 |
Total Liabilities & Shareholder's Equity | 103,857 | 104,251 | 96,716 | 102,616 | 107,987 |
Total Common Equity | 49,915 | 50,191 | 45,850 | 48,790 | 50,528 |
Shares Outstanding | 3,181.80 | 3,164.80 | 3,164.70 | 3,164.70 | 3,164.60 |
Book Value Per Share | 15.69 | 15.86 | 14.49 | 15.42 | 15.97 |